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L angerhans cell histiocytosis (LCH) is a clonal dis-order characterized by the proliferation of 
Langerhans cells in various organs,  which results in 
several types of tissue damage.  In general,  LCH is clas-
sified as the single-system (SS)-type or multi-system 
(MS)-type based on the number of infiltrated organs.  
SS-type patients have unifocal or multifocal involve-
ment in one organ,  such as bones,  skin,  lymph nodes,  
or lungs.  On the other hand,  MS-type patients exhibit 
the involvement of two or more organs.  They require 
chemotherapy and show a 5-year overall survival rate of 
99-100% for those without risk organs such as the liver,  
spleen,  or bone marrow [1-3].  The involvement of risk 
organs such as the hematopoietic system,  liver,  and/or 
spleen show a poor prognosis; furthermore,  a poor 
response to initial chemotherapy results in fetal out-
come [1-3].  The majority of congenital cases include the 
skin region and show spontaneous remission; this type 
of LCH is called “congenital self-healing LCH” or 
“Hashimoto-Pritzker disease”,  but these cases are usu-
ally limited to skin involvement [4 , 5].  Congenital 
MS-type cases have rarely been reported,  and the 
majority of them were fetal [6-8].
We present here a congenital case of MS LCH with 
risk organs who required intensive respiratory care 
because of bilateral multiple lung involvement.  Even 
though induction chemotherapy was not completed,  
the lung disease gradually resolved; therefore,  the 
patient re-started maintenance chemotherapy and 
maintained remission without relapse for more than 4 
years after the end of chemotherapy.  This case might 
suggest that congenital MS LCH even with critical 
organ involvement could be cured with chemotherapy.
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Patients with multi-system (MS)-type langerhans cell histiocytosis (LCH) show poor outcomes,  especially con-
genital MS LCH cases were shown in high mortality rate.  We experienced a congenital case of MS LCH with 
high risk organs,  who needed intensive respiratory support after birth.  Even though intensive chemotherapy 
was discontinued,  this patient’s lung LCH lesions gradually became reduced and his respiratory condition 
recovered; therefore,  we restarted and completed maintenance chemotherapy.  The patient maintained com-
plete remission for more than 4 years after the end of chemotherapy.  Our case suggests that congenital MS LCH 
even with severe organ involvement can be treated successfully with chemotherapy.
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Case
A male infant was born at 38 weeks and 6 days’ ges-
tation after an uncomplicated pregnancy.  He was born 
at 2,684 g with Apgar scores of 9 (1 min) and 10 
(5 min).  He had various types of dermatosis,  such as 
ulcers,  crust,  and abscess at birth.  His blood test 
showed no cytopenia and no elevation of liver function.  
The soluble IL-2 receptor and KL-6 levels were elevated 
(Table 1).  A skin biopsy was performed,  and a patho-
logical examination showed a proliferation of aberrant 
cells,  which had vesicles and kidney-shaped nuclei.  
Immunochemistry showed that these cells were positive 
for CD1a and S-100 protein,  but negative for CD68.  
Therefore,  the patient was given a diagnosis of LCH.  
Computed tomography (CT) showed disease involve-
ment in the bilateral lungs,  liver,  spleen,  cranial bones,  
thymus gland,  and skin lesions noted above (Fig. 1).  
Because the LCH lesions infiltrated and damaged the 
lungs rapidly,  the patient was transferred to another 
hospital for chemotherapy.
Chemotherapy was started according to the Japan 
LCH Study Group (JLSG)-02 induction A protocol 
(Fig. 2A) [3].  Prednisolone was switched to dexameth-
asone palmitate with the expectation of better migration 
to the LCH lesions.  The dose of dexamethasone palmi-
tate was determined according to the HLH-2004 proto-
col [9].  Three days after the start of the chemotherapy,  
pulmonary bulla and bleb from the LCH lung lesions 
caused pneumothorax,  and artificial ventilation was 
required.  Then,  the patient suffered from pneumonia 
with neutropenia and his respiratory status became 
worse.  Therefore,  chemotherapy was discontinued 
(Fig. 2B).  Despite the discontinuance of chemotherapy,  
his respiratory status gradually improved with a 
decrease in lung disease,  and he was extubated after 2 
months of intensive supportive care.  He was admitted 
to our hospital to restart chemotherapy.
At the time of admission,  his SpO2 was 100% with 
ambient air,  and his other vital signs were normal.  On 
physical examination,  he had many types of skin rashes 
and fine crackles at auscultation bilaterally.  Laboratory 
data were normal.  Plain chest CT showed multiple cys-
tic lesions and no pneumothorax (Fig. 3A).  We started 
chemotherapy according to the JLSG-02 maintenance C 
protocol.  The maintenance C protocol comprised vin-
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????? ?　 blood examination data at initial diagnosis
WBC 6,600/µL TP 5.8 g/dL LDH 367 U/L
Neut 85.0% Alb 3.4 g/dL UN 4 mg/dL
Ly 4.0% T-bil 12.2 mg/dL Cre 0.48 mg/dL
Mo 11.0% ALP 464 U/L ferritin 212.2 ng/mL
RBC 450×104/µL AST 26 U/L KL-6 550 U/mL
Hb 16.0 g/dL ALT 9 U/L slL-2R 1,710 U/mL
Plt 26.1×104/µL γ-GT 85 U/L CRP 1.20 mg/dL
WBC,  white blood cell; Neut,  neutrophil; Ly,  lymphocyte; Mo,  monocyte,  RBC,  red blood cell; Hb,  hemoglobin; Plt,  platelet; TP,  
total protein; Alb,  albumin; T-bil,  total bilirubin; ALP,  alkaline phosphatese; AST,  aspartate aminotransferase; ALT,  alanine aminotrans-
ferase; γ-GT,  γ-glutamyltransferase; LDH,  lactate dehydrogenase; UN,  urea nitrogen; Cre,  creatinine; KL-6,  glycoprotein Krebs von den 
Lungen-6; slL-2R,  soluble interleukin-2 receptor; CRP,  C-reactive protein.
???? ?　 Images of computed tomography (CT) at diagnosis.  A,  
LCH lung lesions made multiple nodules and cysts; B,  CT revealed 
hepatomegaly.
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???? ??　 Japan Langerhans Cell Histiocytosis Study Group (JLSG)-02 induction chemotherapy protocol A.
???? ??　 Induction chemotherapy course for this case.  Ara-C,  cytarabine; VCR,  vincristine; Lipo-DEX,  dexamethasone palmi-
tate; PSL,  prednisolone.
???? ?　 A,  CT shows multicystic 
lesions; B,  C,  D,  LCH lung lesions grad-
ually improved with supportive care.
blastine,  prednisolone,  methotrexate and daily oral 
administration of 6-mercaptopurine.  The maintenance 
C regimen lasts for 24 weeks (Fig. 4).  He had no critical 
adverse events and finished approximately 6 months of 
maintenance chemotherapy.  At the time of chemother-
apy completion,  lung cystic lesions remained,  as shown 
by chest CT (Fig. 3B),  and the other organ involve-
ments were diminished.
The cystic lesions had spontaneously decreased 4 
months after the end of maintenance therapy (Fig. 3C).  
At present,  his lung cystic lesions have almost disap-
peared on CT at 4 years after the end of chemotherapy 
(Fig. 3D).
Discussion
Systemic chemotherapy for MS LCH improves the 
prognosis,  but the mortality rate of patients with risk 
organ involvements remains high at 16-38% [1-3].  
Recent studies have shown the importance of therapeu-
tic intensification and prolongation to improve the out-
come of MS LCH [2 , 3].
Congenital MS LCH cases are rarely reported and 
are often fetal [6-8].  We suspected that chemotherapy 
could not be started because patient’s condition would 
be worse in several unreported congenital MS LCH 
cases.  Our congenital case also had several risk organ 
involvements and multiple lung lesions from birth.  We 
started chemotherapy,  but adverse respiratory events 
during induction chemotherapy led to the discontinua-
tion of chemotherapy at the early stage (Fig. 2B).  Then,  
his lung lesions gradually regressed unexpectedly with-
out any chemotherapy.  After that,  the improvement of 
the lung lesions continued under maintenance chemo-
therapy kept,  and they appeared to have disappeared on 
chest CT.
LCH cases with spontaneous regression have been 
reported,  but many of them were congenital skin-local-
ized LCH [4 , 5] or adult lung LCH related to smoking 
[10].  It is considered that MS LCH cases with risk 
organ inevitably need intensive chemotherapy,  so our 
case presented an unusual clinical course.  We suspected 
that the initial 3 days of induction chemotherapy with 
dexamethasone,  cytarabine and vincristin was effective 
for this case and resulted in pneumothorax,  and the 
patient needed artificial ventilation transiently.  The 
recommended intensity of chemotherapy for congenital 
MS-LCH remains unknown,  but mild chemotherapy 
such as steroid alone or supportive therapy alone would 
not be adequate to prevent disease progression.  As a 
sequel to induction chemotherapy,  maintenance che-
motherapy was restarted,  and remission has been 
maintained without relapse.
Recently,  a recurrent BRAF-V600E gene mutation 
has been identified in LCH cases.  The BRAF-V600E 
mutation is reported to be associated with high-risk 
clinical features,  high risk of relapse,  and poor 
response to chemotherapy [11].  In this case,  we did not 
assess the BRAF-V600E mutation because initial sam-
ples were not available for BRAF mutation analysis.  On 
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???? ?　 Japan Langerhans Cell Histiocytosis Study Group (JLSG)-02 maintenance C protocol regimen.  VBL,  vinblastine; PSL,  prednis-
olone; MTX,  methotrexate; 6-MP,  6-mercaptopurine.
the other hand,  one congenital benign LCH case was 
reported to have the BRAF-V600D mutation [12].  
Further genetic study will be needed.
In conclusion,  our case suggests that congenital MS 
LCH cases even with risk organ could be cured by che-
motherapy.  Further study of the prognostic factors and 
treatment intensity for congenital MS LCH is needed.
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